Esophageal cancer
Conditions
Interventions
Gold Standard:Clinical outcomes
is 
by 
ctDNA
Sponsors
Shanghai Changhai Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1. Patients with aged >=18 years old; 2. Patients with clinically or pathologically diagnosed stage I-III esophageal cancer did not receive any anti-tumor treatment before the first blood collection; 3. ECoG score 0 or 1; 4. The subjects and their family members were able to understand the study protocol and were willing to participate in the study and provide written informed consent.
Exclusion criteria
Exclusion criteria: Exclusion criteria: 1. Patients with inflammatory reaction caused by acute and severe diseases in recent period (14 days before blood drawing); or hormone therapy was used in 14 days before blood drawing; 2. Patients with a history of other tumor diseases or with other genetic diseases; 3. Patients who have received organ transplantation, stem cell transplantation, bone marrow transplantation or blood transfusion in recent one month; 4. Pregnant women; 5. Patients who are participating in other clinical trials (including bowel preparation, anesthesia, etc.) who need to take drugs in the past 60 days; 6. Patients with severe cardiovascular disease, uncontrolled infection, or other uncontrollable comorbidities; 7. Patients or family members could not understand the conditions and objectives of this study. Drop-out or withdraw: 1. The subjects or their legal guardians asked to withdraw voluntarily; 2. Patients who violate the inclusion / exclusion criteria; 3. Patients who quit when other unexplained serious complications occur; 4. If pregnancy occurs during the treatment, withdraw from the study; 5. For safety reasons, the sponsor proposed to stop the study; 6. Subjects whose ethics committee decided to stop the study; 7. Subjects who are considered unsuitable by the researcher to continue to participate in the study. Note: the reason and date of withdrawal were recorded in detail, and the withdrawal rate was counted at the end of the study. The subjects who withdrew from the study will take appropriate treatment measures according to the judgment of the researchers in each center.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ctDNA; | — |
Countries
China
Contacts
Public ContactJin Hai
Department of thoracic surgery, Shanghai Changhai Hospital
Outcome results
None listed